Clinical Trial Update: A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ABT-199 (venetoclax) in combination with ibrutinib and rituximab for relapsed/refractory diffuse large B-cell lymphoma has been termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2024-09-23